SELB Selecta Biosciences Inc gains 51% Jun 18, 2021

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; BIND Therapeutics, Inc.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.http://www.priceseries.com/trade/SELB-Selecta-Biosciences-Inc-stock-gains-51-percent-a-Trade-Record-by-priceSeries-2021052020210618.html